MB07133 gets orphan drug status

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

MB07133 gets orphan drug status

SAN DIEGO—Metabasis Therapeutics' MB07133 has received orphan drug status from FDA for the treatment of hepatocellular carcinoma. MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis.

Recent Videos
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Related Content